Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Qlife: LOI (Letter of intent) with major industry player in China for Egoo Health.

By Claus ThestrupCEO, Sweden
Qlife Holding

Qlife: LOI (Letter of intent) with major industry player in China for Egoo Health.

Qlife's management met Hipro Biotechnology's CEO and CSO on this years AACC (Annual Scientific Meeting & Clinical Lab Expo) conference. Now they enter into LOI. Expect a signed agreement later this year.

We host CEO Thomas Warthoe next week for a closer look at the opportunities in China and the agreement with Hipro Biotechnology.

Read full announcement here: Hipro Biotechnology

Participate in next weeks event: Event 19 september 2023

Disclaimer: HC Andersen Capital receives payment from Qlife Holding for a DigitalIR/Corporate Visibility agreement.

Login required

This content is only available for logged in users

Create account

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. The first capsules in the company's product, Egoo.Health Platform, were CE-marked for professional use in early 2020. The company has patent protection for key parts of its technology. The Danish-based company is listed on Nasdaq First North Stockholm.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.